Dr. Reddy's Laboratories (DRREDDY) — Board Meeting

Dr. Reddy's Laboratories reported consolidated revenue of ₹85.5 billion for Q1 FY26, up 11% YoY but flat QoQ, driven by growth in Consumer Healthcare and branded markets. Gross margin declined 350 bps YoY to 56.9% due to pricing pressure, while SG&A rose 13% YoY from strategic investments. Profit before tax was ₹19.0 billion (22.3% margin), down 5% QoQ, with net profit attributable to parent at ₹14.2 billion (16.5% margin), down 11% QoQ. Diluted EPS stood at ₹17.02. EBITDA was ₹22.8 billion (26.7% margin), down 8% QoQ. The board approved a 5:1 stock split effective 28 October 2024, reducing face value from Rs 5 to Rs 1. Strategic updates include Haleon acquisition progress, FDA Form 483 resolution, and CDP 'A' rating. The earnings call was held on July 23, 2025.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does this board meeting affect Dr. Reddy's Laboratories Limited's outlook?" "What did Dr. Reddy's Laboratories Limited announce on 23 July 2025?" "Is this positive or negative for DRREDDY?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 23 July 2025

BPCL Bharat Petroleum Corporation Limited Corporate Action COLPAL Colgate Palmolive (India) Limited Financial Results SRF SRF Limited Financial Results AXISBANK Axis Bank Limited Financial Results SRF SRF Limited Corporate Action DELHIVERY Delhivery Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.